Manish Dhanuka
#910Managing Director
56
Age
10y
Exp
5y
Tenure
8/10
Risk
🎓 B.Tech Chemical Engineering · IIT New Delhi
📜 M.S. Chemical Engineering · University of Akron, USA
🏛️ IIT
CompensationTBP
Personality
7
Open
7
Cons
6
Extr
5
Agre
3
Neur
Orchid Pharma
Healthcare · Small Cap
Distressed / Turnaround · Innovation-Led
About
Manish Dhanuka is the Managing Director of Orchid Pharma, a Small Cap company in the Healthcare sector with a market cap of ₹3K Cr. A Transformational leader with 10 years of experience, he is known for data-driven decision-making and organic builder strategy. Led the company through a significant turnaround by betting heavily on R&D and niche antibiotic segments.
FAQ
What is Manish Dhanuka's leadership style?
Manish Dhanuka is classified as a Transformational leader. He is data-driven in decision-making, with a category creator motivation and startup-speed pace of execution.
What is Manish Dhanuka's educational background?
Manish Dhanuka holds a B.Tech Chemical Engineering from IIT New Delhi and a M.S. Chemical Engineering from University of Akron, USA.
Who is the CEO of Orchid Pharma?
Manish Dhanuka is the Managing Director of Orchid Pharma. He has been with the company for 5 years and in the current role for 5 years.
Leadership DNA
ArchetypeTransformational
MotivationCategory Creator
CrisisRestructurer
DecisionData-Driven
GrowthOrganic Builder
PeopleNumbers Driven
InnovationFast-Follower
PaceStartup-Speed
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployerDemanding Machine
BrandTechnical-Expert
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“Led the company through a significant turnaround by betting heavily on R&D and niche antibiotic segments.”
⚡ Crisis●●●●○
Orchid Pharma underwent a massive corporate debt restructuring and de-merger process to shed non-core assets and focus on specialized APIs and formulations.
🎯 Motivation●●●○○
He has pivoted the company's focus toward niche, high-barrier-to-entry products and complex generic drug development to redefine Orchid's market position.
👥 People●●●●○
His leadership style is explicitly characterized by a data-driven approach to performance management and operational efficiency.
📈 Growth●●●●○
Post-restructuring, the company's growth has been driven by internal R&D investment and operational optimization rather than large-scale M&A.
💡 Innovation●●●●○
The company focuses on high-barrier complex generics and specialty injectables where it competes by scaling production and navigating regulatory approvals post-patent expiry.
🏃 Pace●●●○○
Under new ownership, the company has been aggressively restructuring operations and ramping up manufacturing capacity to regain lost market share.
🌱 Purpose●●●○○
As a company undergoing a post-bankruptcy turnaround, its primary institutional focus is on debt reduction and restoring profitability to satisfy creditors and shareholders.
🏷️ Brand●●●●○
The company is historically recognized for its specialized capabilities in cephalosporin antibiotics and complex chemical synthesis.
🤝 Customer●●●●●
Orchid Pharma operates primarily as a B2B player, supplying APIs and finished dosage forms to global pharmaceutical distributors and institutional partners.
💼 Employer●●●○○
The turnaround phase necessitates a high-pressure environment focused on operational efficiency and aggressive performance targets to ensure viability.
📋 Mandate
Requires radical operational realignment and debt management to regain profitability following significant past volatility.
🏢 Culture●●●●○
Post-restructuring, the firm is heavily focused on R&D-centric pharma recovery, necessitating a move toward scientific experimentation and product-focused development.
Financials
Revenue FY25₹914 Cr
PAT FY25₹100 Cr
Rev CAGR 5Y17.8%
OPM10.6%
NPM10.9%
ROE7.9%
ROCE6.9%
P/E136.9
Fwd P/E18.8
P/B2
D/E22.1
Promoter69.8%
Institutional17.1%
Mkt Cap₹3K Cr
Compensation
To Be Published
Data being verified from audited reports
